Recently, the prices of multivitamins are rising sharply. After the continuous increase of vitamin B 1 in the past year, vitamin B2 (riboflavin), calcium pantothenate (calcium pantothenate) and vitamin B6 all increased significantly. The data showed that the price of calcium pantothenate rose from 2065,438+065,438+0 in February 2005 to 65,438+050 yuan/kg ~ 65,438+060 yuan/kg, which was nearly three times higher than that of 438+0 in June 2065. Although there is overcapacity in the domestic market, driven by the supply-side reform, the vitamin industry began to reduce production and integrate, and the rigid demand downstream also provided support for the price increase. Dai, an analyst at Guohai Securities [0.00% fund research report], believes that with the acceleration of chemical de-capacity, the follow-up vitamin sector is expected to continue to increase prices. 1. The entry of new production capacity is limited and the supply is shrinking. Under the framework of supply-side reform, the environmental supervision standards of chemical enterprises tend to be strict. The short-term supply contraction of industry is the general trend. 2. Downstream demand rigidity provides support for price increase. Although the growth of vitamin market is slow in recent years, this product is mainly used in medicine and feed, which is irreplaceable and belongs to rigid demand. With the contraction of the supply side, the space and extent of price increase may be relatively large. 3. Core manufacturers have a strong willingness to raise prices. The low prices of major manufacturers in the early stage lead to poor operating conditions, and the price increase of products can greatly increase gross profit and improve operating conditions, so manufacturers have a strong willingness to raise prices.
According to China Feed Industry Information Network, Guangji Pharmaceutical recently raised the price of vitamin B2 to 185 yuan (kg price, the same below), which was nearly 50% higher than the price of 123 yuan ~ 125 yuan in early September. It is understood that the reason why Guangji Pharmaceutical has greatly increased the quotation of vitamin B2 is related to the recent tight market supply and increased production costs. It is reported that the feed-grade vitamin B2 of Chifeng Pharmaceutical Co., Ltd., a subsidiary of Shanghai Haijianuo Pharmaceutical Co., Ltd., was recently revoked by the European Commission's FAMI-QS (European Feed Additive and Premixed Feed Quality System) certificate because of the genetically modified incident, and it is no longer possible to enter the EU market. At the same time, DSM, an international supplier of vitamin B2, announced that it would stop production for six weeks in June+10, 5438, which made the market supply tight. At present, the price of corn starch, the raw material of vitamin B2, has reached 3200 yuan/ton to 3500 yuan/ton, and the price has been rising continuously in recent years, which makes the production cost of vitamin B2 increase. Coupled with the genetically modified event, enterprises are urged to improve their export requirements, and production costs are correspondingly increased. At the beginning of September, domestic manufacturers of vitamin B2 slightly raised the price to 123 yuan ~ 125 yuan and then stopped reporting. According to industry insiders, a new round of price increases is brewing.